Accessibility Menu
Atrium Therapeutics logo

Atrium Therapeutics(NASDAQ) RNA

Current Price$11.52
Market Cap$196.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)-22%
5 YearN/A
1 YearN/A
1 Month-10%
Atrium Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 11.492026-07-24
Atrium Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.43%USD 12.152026-07-17
1 month-10.44%USD 12.832026-06-24
3 month-14.83%USD 13.492026-04-24
Since inception-22.1%USD 14.752026-02-27

Atrium Therapeutics Financials at a Glance

Market Cap

$196.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$25.04

Net Income (TTM)

-$64.73

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.32 (Low)

Price

$11.52

Volume

120,943.813

Open

$11.98

Previous Close

$11.49

Daily Range

$11.48 - $11.98

52-Week Range

$11.40 - $16.77

Estimated Earnings Date

Aug 13, 2026

RNA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Atrium Therapeutics

Atrium Therapeutics creates medicines for people with rare genetic heart conditions. These treatments help patients whose heart muscles cannot function properly. The company uses a unique delivery system to send medicine directly to the heart.

The Precision Cardiology Pipeline

  • ATR 1072: Lead medicine for PRKAG2 syndrome; uses small interfering ribonucleic acid (siRNA) to silence disease-causing genes in the heart.
  • ATR 1086: siRNA-based therapy for PLN cardiomyopathy; designed to reduce levels of a protein that causes heart failure.
  • Research Programs: Early-stage projects for rare cardiology diseases; leverages a platform that combines targeted antibodies with genetic molecules.
  • Partnered Services: Collaborative research and development work; generates revenue through agreements with large pharmaceutical firms.

A New Independent Path

  • Separated from Avidity Biosciences in February 2026 to become an independent public company.
  • Received $270 million in initial cash funding during the corporate split in February 2026.
  • Earned a $15 million milestone payment from Bristol Myers Squibb in early 2026.
  • Achieved a clinical development milestone under a research agreement with Eli Lilly in August 2025.

What Makes the Technology Different

The company uses a delivery platform that combines the targeting ability of antibodies with the precision of genetic medicine. This approach allows treatments to reach heart tissue that was previously difficult to target with traditional drugs.

The Q1 2026 Scorecard

  • Revenue grew to $19.6 million in Q1 2026, up from $1.6 million in Q1 2025.
  • Operating loss worsened to $17.3 million in Q1 2026 from a $7.5 million loss in 2025.
  • Net loss deepened to $16.6 million in Q1 2026, compared to $7.4 million in Q1 2025.
  • Cash and equivalents totaled $267.8 million at the end of March 2026.

Bottom Line

Atrium has evolved from a research division into a standalone company focused on genetic heart medicine. Its success depends on moving its two lead therapies through clinical testing using its current cash reserves.

AI Generated • May 19, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Kathleen Gallagher

Website

www.atriumtherapeutics.com

Headquarters

San Diego, CA 92121, US

RNA Financials

Key Financial Metrics (TTM)

Gross Margin

99.26%

Operating Margin

-318.70%

Net Income Margin

-315.71%

Return on Equity

-29.67%

Return on Capital

-36.41%

Return on Assets

-22.13%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$196.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

17.11M

Volume

120.94K

Avg. Volume

214.86K

Financials (TTM)

Gross Profit

$20.34M

Operating Income

-$65.32M

EBITDA

-$64.40M

Operating Cash Flow

-$50.40M

Capital Expenditure

-$2.98M

Free Cash Flow

-$53.37M

Cash & ST Invst.

$267.85M

Total Debt

$2.68M

Atrium Therapeutics Performance Analysis

Atrium Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-12-31USD 9,764,000N/A
20242024-12-31USD 10,897,00011.6%
20252025-12-31USD 18,618,00070.9%
Atrium Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-312185.8%
Atrium Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-12-31USD -0.37N/A
20242024-12-31USD -1.47293.4%
20252025-12-31USD -2.8997.0%
Atrium Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-3142.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$19.64M

N/A

Gross Profit

$19.48M

N/A

Gross Margin

99.23%

N/A

Market Cap

$196.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$384.62K

N/A

Employees

511

N/A

Net Income

-$16.63M

N/A

EBITDA

-$16.48M

N/A

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$267.85M

N/A

Total Debt

$2.68M

N/A

Accounts Receivable

$15.00M

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$2.68M

N/A

Return on Assets

-22.13%

N/A

Return on Invested Capital

-24.15%

N/A

Free Cash Flow

-$33.24M

N/A

Operating Cash Flow

-$31.14M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,413.98+0.00%
^DJIDJI
$51,907.48+0.00%
^IXICNASDAQ
$25,011.87-0.01%
BTCBitcoin
$64,083.00-0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About RNA

What is the current price of Atrium Therapeutics?

Atrium Therapeutics is trading at $11.49 per share.

What is the 52-week range for Atrium Therapeutics?

Over the past 52 weeks, Atrium Therapeutics has traded between $11.40 and $16.77.

How much debt does Atrium Therapeutics have?

As of the most recent reporting period, Atrium Therapeutics reported total debt of $2.68M.

How much cash does Atrium Therapeutics have on hand?

Atrium Therapeutics reported $267.85M in cash and cash equivalents in its most recent financial results.

What is Atrium Therapeutics’s dividend yield?

Atrium Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services